Neuroinflammation of the nigrostriatal pathway during progressive 6‐OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging

We investigated the microglial response to progressive dopamine neuron degeneration using in vivo positron emission tomography (PET) imaging and postmortem analyses in a Parkinson's disease (PD) rat model induced by unilateral (right side) intrastriatal administration of 6‐hydroxydopamine (6‐OHDA). Degeneration of the dopamine system was monitored by PET imaging of presynaptic dopamine transporters using a specific ligand 11C‐CFT (2β‐carbomethoxy‐3β‐(4‐fluorophenyl) tropane). Binding of 11C‐CFT was markedly reduced in the striatum indicating dopaminergic degeneration. Parallel PET studies of 11C‐PK11195 (1‐(2‐chlorophenyl)‐N‐methyl‐N‐(1‐methylpropyl)‐3 isoquinoline carboxamide) (specific ligand for activated microglia) showed increased binding in the striatum and substantia nigra indicative of a microglial response. Postmortem immunohistochemical analyses were performed with antibodies against CR3 for microglia/macrophage activation. Using a qualitative postmortem index for microglial activation we found an initially focal, then widespread microglial response at striatal and nigral levels at 4 weeks postlesion. These data support the hypothesis that inflammation is a significant component of progressive dopaminergic degeneration that can be monitored by PET imaging.

[1]  I. Mackenzie.  Activated microglia in dementia with Lewy bodies , 2000, Neurology.

[2]  G. Bing,et al.  Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats , 2000, Neuroscience.

[3]  W. Galpern,et al.  In vivo PET Imaging in rat of dopamine terminals reveals functional neural transplants , 1998, Annals of neurology.

[4]  M. Graeber,et al.  New expression of myelomonocytic antigens by microglia and perivascular cells following lethal motor neuron injury , 1990, Journal of Neuroimmunology.

[5]  B. Jenkins,et al.  Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease. , 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[7]  P. Mcgeer,et al.  The importance of inflammatory mechanisms in alzheimer disease , 1998, Experimental Gerontology.

[8]  A. Björklund,et al.  Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat , 1996, Neuroscience.

[9]  G L Brownell,et al.  Dopamine fiber detection by [11C]-CFT and PET in a primate model of parkinsonism , 1992, Neuroreport.

[10]  Richard S. J. Frackowiak,et al.  [3H]PK 11195 and the localisation of secondary thalamic lesions following focal ischaemia in rat motor cortex , 1991, Neuroscience Letters.

[11]  P. Mcgeer,et al.  Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR , 1987, Neuroscience Letters.

[12]  M. Menziani,et al.  Mapping the peripheral benzodiazepine receptor binding site by conformationally restrained derivatives of 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3- isoquinolinecarboxamide (PK11195). , 1997, Journal of medicinal chemistry.

[13]  André Syrota,et al.  Synthesis of N‐(11C) methyl, N‐(methyl‐1 propyl), (chloro‐2 phenyl)‐1 isoquinoleine carboxamide‐3 (PK 11195): A new ligand for peripheral benzodiazepine receptors , 1984 .

[14]  Bruce G. Jenkins,et al.  Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease , 1998, Nature Medicine.

[15]  A. Bjo¨rklund,et al.  Astroglial response in the excitotoxically lesioned neostriatum and its projection areas in the rat , 1987, Neuroscience.

[16]  J. Langston,et al.  Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.

[17]  A. Björklund,et al.  Studies on Neuroprotective and Regenerative Effects of GDNF in a Partial Lesion Model of Parkinson's Disease , 1997, Neurobiology of Disease.

[18]  A. Członkowska,et al.  The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse , 1999, Experimental Neurology.

[19]  R B Banati,et al.  PK (‘peripheral benzodiazepine’) – binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK 11195 binding to activated microglia , 1997, Journal of neurocytology.

[20]  S. Daniel,et al.  Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[21]  Roger N Gunn,et al.  In-vivo measurement of activated microglia in dementia , 2001, The Lancet.

[22]  F E Turkheimer,et al.  [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen’s encephalitis , 1999, Neurology.

[23]  P. Mcgeer,et al.  Microglial response to 6-hydroxydopamine-induced substantia nigra lesions , 1989, Brain Research.

[24]  M. Abercrombie.  Estimation of nuclear population from microtome sections , 1946, The Anatomical record.

[25]  Kenneth E. Newhouse,et al.  The Metabolism of the Human Brain Studied with Positron Emission Tomography , 1985, The Yale Journal of Biology and Medicine.

[26]  W. H. Oertel,et al.  Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.

[27]  O. Isacson,et al.  Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease , 2001, The European journal of neuroscience.

[28]  Alan C. Evans,et al.  PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis , 1997, Journal of neuroscience research.

[29]  P. Mcgeer,et al.  Inflammation in Parkinson's disease. , 2001, Advances in neurology.

[30]  P. Damier,et al.  Glial cells and inflammation in parkinson's disease: A role in neurodegeneration? , 1998, Annals of neurology.

[31]  R Tomczak,et al.  In vivo imaging of activated microglia using [11 C]PK11195 and positron emission tomography in patients after ischemic stroke , 2000, Neuroreport.

[32]  A. Członkowska,et al.  Inflammatory changes in the substantia nigra and striatum following MPTP intoxication , 2000, Annals of neurology.

[33]  S. Appel,et al.  Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. , 1998, Archives of neurology.

[34]  G. L. Watkins,et al.  PET Imaging of human gliomas with ligands for the peripheral benzodiazepine binding site , 1989, Annals of neurology.

[35]  M. Graeber,et al.  Synaptic stripping in the human facial nucleus , 2004, Acta Neuropathologica.

[36]  R B Banati,et al.  Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK11195 , 2000, Neurology.

[37]  L. Lue,et al.  Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. , 1996, Journal of neuropathology and experimental neurology.

[38]  P. Mcgeer,et al.  Familial nature and continuing morbidity of the amyotrophic lateral sclerosis-parkinsonism dementia complex of Guam , 1997, Neurology.